A phase II study of Gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: A hoosier oncology group study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 5, 2011, Pages 460-465

  Cardenes, Higinia R ^a   Moore, Annette M ^e   Johnson, Cynthia S ^b   Yu, Menggang ^b   Helft, Paul ^a   Chiorean, Elena G ^a   Vinson, Jacob ^c   Howard, Thomas J ^a   Stephens, Anthony W ^f   Tai, D Fritz ^d,g   Loehrer, Patrick J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c Hoosier Oncology Group   (United States)

^d Eli Lilly Oncology   (United States)

^e Howard Regional Health System   (United States)

^f Oncology Hematology Associates of SW Indiana ^*  (United States)

^g Cancer Care Center of Southern Indiana   (United States)

Author keywords

gemcitabine; locally advanced unresectable pancreatic cancer; radiation therapy

Indexed keywords

ALKALINE PHOSPHATASE; BILIRUBIN; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHOLANGITIS; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEMALE; FOLLOW UP; GRANULOCYTOPENIA; HUMAN; HYPERBILIRUBINEMIA; INFECTION; INOPERABLE CANCER; LEUKOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; RADIATION DOSE FRACTIONATION; RADIATION SAFETY; RADIATION SICKNESS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT PLANNING; TREATMENT RESPONSE; VOMITING; WEAKNESS;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BRACHYTHERAPY; CARCINOMA, ADENOSQUAMOUS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80053372502     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181e9c103     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics. CA Cancer J Clin. 2009;59:225-249.
2. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators [comment]. J Gastrointest Surg. 2000;4:567-579.
3. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg. 1995;221:721-731; discussion 723-731.
4. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer. 1981;48:1705-1710. (Pubitemid 11022870)
5. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst. 1988;80:751-755.
6. Klaassen DJ, MacIntyre JM, Catton GE, et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil-an Eastern Cooperative Oncology Group study. J Clin Oncol. 1985;3:373-378. (Pubitemid 15132005)
7. Huguet F, Andre T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR Phase II and III studies. J Clin Oncol. 2007;25:326-331. (Pubitemid 350003022)
8. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial [comment]. J Clin Oncol. 1997;15:2403-2413. (Pubitemid 27251144)
9. Hoffman JP, McGinn CJ, Szarka C, et al. A Phase I study of preoperative Gemcitabine (GEM) with radiation therapy (RT) followed by postoperative Gemcitabine for patients with localized, resectable pancreatic adenocarcinoma (PAC). Pro Am Soc Clin Oncol. 1998;17:283a. Abstract 1090.
10. Blackstock AW, Bernard SA, Richards F, et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer [comment]. J Clin Oncol. 1999;17:2208-2212. (Pubitemid 29318854)
11. Blackstock AW, Tepper JE, Niedwiecki D, et al. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer. 2003;34:107-116. (Pubitemid 39279726)
12. Epelbaum R, Rosenblatt E, Nasrallah S, et al. Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. J Surg Oncol. 2002;81: 138-143. (Pubitemid 35253625)
13. McGinn CJ, Zalupski MM, Shureiqi I, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2001;19:4202-4208. (Pubitemid 33081637)
14. McGinn CJ, Talamonti MS, Small W Jr, et al. A Phase II trial of full-dose gemcitabine with concurrent radiation therapy in patients with resectable or unresectable nonmetastatic pancreatic cancer. Paper presented at: ASCO 2004 Gastrointestinal Cancer Symposium; 2004; Alexandria, VA.
15. Wolff RA, Evans DB, Gravel DM, et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res. 2001;7: 2246-2253. (Pubitemid 32751621)
16. Ikeda M, Okada S, Tokuuye K, et al. A Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br J Cancer. 2002;86:1551-1554. (Pubitemid 34628107)
17. American Joint Committee on Cancer. Exocrine pancreas. In: Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002:157-164.
18. The National Cancer Institute. Cancer Therapy Evaluation Program. Common Toxicity Criteria Manual CTC. Vol 2.0. Bethesda, MD: NCI 1999.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada [comment]. J Natl Cancer Inst. 2000;92:205-216.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457.
21. Lawrence TS, Chang EY, Hahn TM, et al. Radiosensitization of pancreatic cancer cells by 20,20-difluoro-20-deoxycytidine. Int J Radiat Oncol Biol Phys. 1996;34:867-872.
22. de Lange SM, van Groeningen CJ, Meijer OW, et al. Gemcitabineradiotherapy in patients with locally advanced pancreatic cancer. Eur J Cancer. 2002;38:1212-1217. (Pubitemid 34603482)
23. Pipas JM, Mitchell SE, Barth RJ Jr, et al. Phase I study of twiceweekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 2001;50:1317-1322. (Pubitemid 32727811)
24. Small W Jr, Berlin J, Freedman GM, et al. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer:a multicenter Phase II trial [comment]. J Clin Oncol. 2008;26:942-947. (Pubitemid 351398088)
25. Allen AM, Zalupski MM, Robertson JM, et al. Adjuvant therapy in pancreatic cancer: phase I trial of radiation dose escalation with concurrent full-dose gemcitabine. Int J Radiat Oncol Biol Phys. 2004;59:1461-1467. (Pubitemid 38954069)
26. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomized controlled trial [comment]. Lancet. 2001; 358:1576-1585. (Pubitemid 33101907)
27. Loehrer PJ, Powell ME, Cardenes HR, et al. Eastern Cooperative Oncology Group. A randomized Phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol. 2008;26:214s. Abstract 4506.